<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05045534</url>
  </required_header>
  <id_info>
    <org_study_id>TB-840-PRT-01</org_study_id>
    <nct_id>NCT05045534</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability and Pharmacokinetics of TB-840 in Healthy Subjects</brief_title>
  <official_title>A Dose Block-randomized, Double-blind, Placebo Controlled, Single-/Multiple-dosing, Dose-escalation Phase 1 Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetic Characteristics of TB-840 (NASH Treatment Candidate) After Oral Administration in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Therasid Bioscience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Therasid Bioscience</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a dose block-randomized, double-blind, placebo-controlled, single- and&#xD;
      multiple-ascending dose study. For each dose group, 6 subjects will be randomly assigned to&#xD;
      the test group (TB-840) and 2 subjects will be randomly assigned to the control group&#xD;
      (placebo). Adverse event (AE) monitoring, physical examination, vital signs, ECG, clinical&#xD;
      laboratory test will be done for safety and tolerability assessment, and blood and urine&#xD;
      samples will be collected for Pharmacokinetic (PK) assessment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.03</measure>
    <time_frame>Up to 10 days from single ascending dose</time_frame>
    <description>Incidences of treatment-emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.03</measure>
    <time_frame>Up to 14 days from multiple ascending dose</time_frame>
    <description>Incidences of treatment-emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of drug in plasma[Cmax]</measure>
    <time_frame>Up to 4 days from single ascending dose</time_frame>
    <description>Pharmacokinetic Profile of TB-840</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of drug in plasma[Cmax]</measure>
    <time_frame>Up to 8 days from multiple ascending dose</time_frame>
    <description>Pharmacokinetic Profile of TB-840</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma drug concentration-time curve[AUC]</measure>
    <time_frame>Up to 4 days from single ascending dose</time_frame>
    <description>Pharmacokinetic Profile of TB-840</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma drug concentration-time curve[AUC]</measure>
    <time_frame>Up to 8 days from multiple ascending dose</time_frame>
    <description>Pharmacokinetic Profile of TB-840</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1 Single Dose SD1 (first dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group SD1 a first single dose of TB-840(n=6) or placebo(n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Single Dose SD2 (second dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group SD2 a first single dose of TB-840(n=6) or placebo(n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 Single Dose SD3 (third dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group SD3 a first single dose of TB-840(n=6) or placebo(n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 Single Dose SD4 (fourth dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group SD4 a first single dose of TB-840(n=6) or placebo(n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5 Single Dose SD5 (fifth dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group SD5 a first single dose of TB-840(n=6) or placebo(n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 Single Dose SD6 (sixth dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group SD6 a first single dose of TB-840(n=6) or placebo(n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7 Single Dose SD7 (seventh dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group SD7 a first single dose of TB-840(n=6) or placebo(n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8 Single Dose SD8 (eighth dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group SD8 a first single dose of TB-840(n=6) or placebo(n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9 : Mutiple Dose MD1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group MD1 a first multiple dose of TB-840(n=6) or placebo(n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 10 : Mutiple Dose MD2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group MD2 a first multiple dose of TB-840(n=6) or placebo(n=2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 11 : Mutiple Dose MD3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group MD3 a first multiple dose of TB-840(n=6) or placebo(n=2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparison of TB-840 treatment with Placebo</intervention_name>
    <description>Single dose or Multiple Dose of TB-840 treatment</description>
    <arm_group_label>Cohort 1 Single Dose SD1 (first dose)</arm_group_label>
    <arm_group_label>Cohort 10 : Mutiple Dose MD2</arm_group_label>
    <arm_group_label>Cohort 11 : Mutiple Dose MD3</arm_group_label>
    <arm_group_label>Cohort 2 Single Dose SD2 (second dose)</arm_group_label>
    <arm_group_label>Cohort 3 Single Dose SD3 (third dose)</arm_group_label>
    <arm_group_label>Cohort 4 Single Dose SD4 (fourth dose)</arm_group_label>
    <arm_group_label>Cohort 5 Single Dose SD5 (fifth dose)</arm_group_label>
    <arm_group_label>Cohort 6 Single Dose SD6 (sixth dose)</arm_group_label>
    <arm_group_label>Cohort 7 Single Dose SD7 (seventh dose)</arm_group_label>
    <arm_group_label>Cohort 8 Single Dose SD8 (eighth dose)</arm_group_label>
    <arm_group_label>Cohort 9 : Mutiple Dose MD1</arm_group_label>
    <other_name>TB-840</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults aged ≥ 19 and ≤ 45 years at the time of screening visit&#xD;
&#xD;
          -  BMI of ≥ 18.0 and ≤ 27.0 kg/m2 at the time of screening visit&#xD;
&#xD;
          -  Clinically confirmed as healthy based on the medical history, physical examination,&#xD;
             vital signs, electrocardiography (ECG), and proper laboratory tests (Subjects with&#xD;
             values out of the normal range may participate in the study if they are deemed&#xD;
             clinically insignificant by the investigator.)&#xD;
&#xD;
          -  Agree to use medically acceptable methods of contraception by participant, his/her&#xD;
             spouse, or partner and not to donate sperm or oocyte from the date of the first dose&#xD;
             of the investigational product (IP) until 90 days after the last dose of the IP&#xD;
&#xD;
          -  Examples of medically acceptable methods of contraception&#xD;
&#xD;
          -  Females (females who use oral hormonal contraceptives and subcutaneous hormonal&#xD;
             contraceptive implants may be excluded from the study)&#xD;
&#xD;
          -  Use of an intrauterine device with a proven pregnancy failure rate&#xD;
&#xD;
          -  Use of barrier method with spermicide&#xD;
&#xD;
          -  Surgical sterilization (salpingectomy/tubal ligation, hysterectomy, etc.)&#xD;
&#xD;
          -  Males&#xD;
&#xD;
          -  Use of barrier method with spermicide&#xD;
&#xD;
          -  Surgical sterilization (vasectomy, vasoligation, etc.)&#xD;
&#xD;
          -  Voluntarily decided to participate in the study and provided written consent to comply&#xD;
             with the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or history of a clinically significant hepatic, renal, gastrointestinal,&#xD;
             respiratory, musculoskeletal, endocrine, neuropsychiatric, hemato-oncological, or&#xD;
             cardiovascular disease&#xD;
&#xD;
          -  History of gastrointestinal diseases (e.g., Crohn's disease, ulcer, etc.) or surgery&#xD;
             (excluding simple appendectomy or hernia repair) that may affect the absorption of the&#xD;
             investigational products&#xD;
&#xD;
          -  History of clinically significant hypersensitivity to drugs containing RORα agonist or&#xD;
             other ingredients of the same class, or other drugs (aspirin and non-steroidal&#xD;
             anti-inflammatory drugs, antibiotics, etc.)&#xD;
&#xD;
          -  History of drug abuse or positive result from urine drug screening of drugs with&#xD;
             concerns of drug abuse&#xD;
&#xD;
          -  Subjects with any of the following results at the time of screening visit:&#xD;
&#xD;
          -  Systolic blood pressure: &lt; 90 mmHg or &gt; 140 mmHg&#xD;
&#xD;
          -  Diastolic blood pressure: &lt; 50 mmHg or &gt; 90 mmHg&#xD;
&#xD;
          -  Heart rate: &lt; 50 bpm or &gt; 100 bpm&#xD;
&#xD;
          -  AST: &gt; x 1.5 ULN&#xD;
&#xD;
          -  ALT: &gt; x 1.5 ULN&#xD;
&#xD;
          -  ALP: &gt; x 1.5 ULN&#xD;
&#xD;
          -  T.bil: &gt; x 1.5 ULN&#xD;
&#xD;
          -  γ-GT： &gt; x 1.5 ULN&#xD;
&#xD;
          -  Serum creatinine: &gt; x 1.5 ULN&#xD;
&#xD;
          -  Participated in another bioequivalence study or clinical study and have been exposed&#xD;
             to an investigational product within 6 months prior to the date of the first dose of&#xD;
             this study&#xD;
&#xD;
          -  Donated whole blood within 2 months or blood components within 1 month, or received&#xD;
             blood transfusion within 1 month prior to the date of the first dose of this study&#xD;
&#xD;
          -  Use of drug-metabolizing enzyme inducer or inhibitor such as barbiturates within 1&#xD;
             month prior to the date of the first dose of this study&#xD;
&#xD;
          -  Consumption of caffeine- or grapefruit-containing foods or beverages within 3 days&#xD;
             prior to the date of the first dose of this study&#xD;
&#xD;
          -  Use of any prescription drugs or herbal medicines within 1 month, or any&#xD;
             over-the-counter (OTC) drugs within 1 week prior to the date of the first dose of this&#xD;
             study (Subjects may participate in the study if such use is judged not to&#xD;
             significantly affect the assessment of safety and pharmacokinetics by the&#xD;
             investigator.)&#xD;
&#xD;
          -  Excessive intake of caffeine, excessive intake of alcohol, or heavy smoking (caffeine&#xD;
             &gt; 5 units/day, alcohol &gt; 21 units/week [1 unit = 10 mL of pure alcohol], smoking &gt; 10&#xD;
             cigarettes/day)&#xD;
&#xD;
          -  Unable to consume meals provided by the study site&#xD;
&#xD;
          -  Prior participation in this study&#xD;
&#xD;
          -  Positive result in serology tests (hepatitis B tests, human immunodeficiency virus&#xD;
             [HIV] tests, hepatitis C tests, or syphilis tests [RPR])&#xD;
&#xD;
          -  Determined inappropriate for the study by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>YoungHee Shin</last_name>
    <phone>+82317070737</phone>
    <email>yhshin@therasidbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yunji Lee</last_name>
    <phone>+82317070737</phone>
    <email>yjlee@therasidbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Therasid Bioscience</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13488</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YoungHee Shin</last_name>
      <phone>+82317070737</phone>
      <email>yhshin@therasidbio.com</email>
    </contact>
    <investigator>
      <last_name>Sang Won Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

